SCHEMBL7008064

SCHEMBL7008064

COc1ccc2nc([S+]([O-])Cc3ncc(C)c(OC)c3C)n(S(=O)(=O)c3ccc(OCC(N)=O)cc3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.42
ALDH1A1 P00352 4/20 0.38
HTT P42858 4/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
WDR5 P61964 2/20 0.38
BRS3 P32247 2/20 0.38
ATP1A1 P05023 2/20 0.38
ATP1B1 P05026 2/20 0.38
ATP1A3 P13637 2/20 0.38
ATP1B2 P14415 2/20 0.38
ATP4A P20648 2/20 0.38
ATP1A2 P50993 2/20 0.38
ATP4B P51164 2/20 0.38
ATP1B3 P54709 2/20 0.38
FXYD2 P54710 2/20 0.38
ATP1A4 Q13733 2/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
DDAH1 O94760 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7007013 0.94 CYP2C9 (0.40) CYP2C9ALDH1A1HTTKMT2ASMN1; SMN2
SCHEMBL5332710 0.93 CYP2C9 (0.42) CYP2C9ALDH1A1HTTKMT2ASMN1; SMN2
SCHEMBL5332714 0.93 CYP2C9 (0.42) CYP2C9ALDH1A1HTTKMT2ASMN1; SMN2
SCHEMBL5763595 0.93 CYP2C9 (0.42) CYP2C9ALDH1A1HTTKMT2ASMN1; SMN2
SCHEMBL5763585 0.93 CYP2C9 (0.42) CYP2C9ALDH1A1HTTKMT2ASMN1; SMN2
SCHEMBL7231352 0.93 CYP2C9 (0.40) CYP2C9ALDH1A1HTTKMT2ASMN1; SMN2
SCHEMBL14495759 0.92 CYP2C9 (0.42) CYP2C9ALDH1A1HTTKMT2ASMN1; SMN2
SCHEMBL5367365 0.92 CYP2C9 (0.42) CYP2C9ALDH1A1HTTKMT2ASMN1; SMN2
SCHEMBL5370630 0.92 CYP2C9 (0.42) CYP2C9ALDH1A1HTTKMT2ASMN1; SMN2
SCHEMBL7010700 0.92 CYP2C9 (0.38) CYP2C9ALDH1A1HTTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6559167-B1 Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-05-06 US claimed
EP-1105387-B1 PRODRUGS OF PROTON PUMP INHIBITORS WINSTON PHARMATEUTICALS LLC (US) 2003-01-29 EP claimed
US-7294716-B2 Process for preparing isomerically pure prodrugs of proton pump inhibitors ALLERGAN, INC. (US) 2007-11-13 US disclosed
US-6559167-B1 Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-05-06 US disclosed
EP-1105387-B1 PRODRUGS OF PROTON PUMP INHIBITORS WINSTON PHARMATEUTICALS LLC (US) 2003-01-29 EP disclosed